Food for thought that the primary endpoint is only pain when PR is pushing PPS as the holy grail for DMOAD. I understand aiming for an easier target (pain) if that is more likely to achieve approval. However, if pain is the main labelling on the product it brings into question the revenue potential. Will doctors have enough confidence to prescribe it for treatment of the actual disease? Will governments and insurers pay $2,500 for something primarily labelled as a painkiller?
Perhaps PR was pushing the holy grail line so much at the same time he invited potential partners to talk with Paradigm as he thinks a large pharma might be better placed to bridge the gap. ie. perhaps a large pharma will be able to market PPS as a DMOAD even with the painkilling label better than Paradigm can do.
PAR Price at posting:
$2.38 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)